Connor, Clark & Lunn Investment Management (CC&L)
STOK icon

Connor, Clark & Lunn Investment Management (CC&L)’s Stoke Therapeutics STOK Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-45,575
Closed -$484K – 1533
2023
Q2 		$484K Sell
45,575
-6,360
-12% -$67.7K ﹤0.01% 990
2023
Q1 		$433K Sell
51,935
-4,190
-7% -$37.8K ﹤0.01% 924
2022
Q4 		$518K Buy
56,125
+15,887
+39% +$165K ﹤0.01% 854
2022
Q3 		$517K Buy
40,238
+23,077
+134% +$368K ﹤0.01% 810
2022
Q2 		$227K Buy
17,161
+5,204
+44% +$79.1K ﹤0.01% 910
2022
Q1 		$252K Buy
11,957
+2,562
+27% +$51.3K ﹤0.01% 909
2021
Q4 		$225K Buy
+9,395
New +$224K ﹤0.01% 954

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s STOK Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Stoke Therapeutics (STOK) in Q3 2023, closing a stake of 45,575 shares — an estimated $484K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in STOK in Q4 2021 and held it in 7 quarters. The position peaked at $518K in Q4 2022. 96 funds tracked by Wall St. Rank hold STOK as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Stoke Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 45,575 Stoke Therapeutics shares in Q3 2023, an estimated $484K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Stoke Therapeutics in Q4 2021 and held it in 7 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Stoke Therapeutics position peaked at $518K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.